MedTrace Logo

Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

NCT01387737 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1299

Last updated 2026-01-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of TA-7284 as monotherapy or combination therapy with other oral anti-hyperglycaemic agent in Japanese patients with Type 2 diabetes mellitus on 52 weeks oral administration.

Conditions

Interventions

DRUG

TA-7284-Low

TA-7284-Low

DRUG

TA-7284-High

TA-7284-High

Sponsors & Collaborators

  • Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • Nobuya Inagaki, M.D. · Kyoto University, Graduate School of Medicine

  • Kazuoki Kondo, M.D. · Tanabe Pharma Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-11-30
Completion
2012-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01387737 on ClinicalTrials.gov